Literature DB >> 2513642

Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole.

W Creutzfeldt1, R Lamberts, F Stöckmann, G Brunner.   

Abstract

A total of 36 patients with chronic gastric or oesophageal peptic ulceration (including 6 with antrectomy), resistant to high-dose ranitidine treatment for at least 3 months, were successfully treated with omeprazole 20-60 mg/day, for periods up to 3 years. Fasting serum gastrin levels were monitored at regular intervals during therapy and multiple gastric mucosal biopsies were taken during gastroscopy every 3-6 months. Gastrin levels increased significantly during the first 6 months of therapy from a mean of 81.5 to 206 pg/ml; a slight decrease was observed thereafter. There was no significant increase in the volume density of argyrophilic cells in the oxyntic mucosa. No clusters of endocrine cells were found in the oxyntic mucosa and no change of G-cell volume density occurred in the antral mucosa under therapy. Omeprazole therapy did not result in any changes in gastrin levels or oxyntic argyrophilic cells in the antrectomized patients. It is concluded that the moderate hypergastrinaemia observed during long-term omeprazole treatment in man does not induce hyperplasia of argyrophilic cells in the oxyntic mucosa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513642     DOI: 10.3109/00365528909091259

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  12 in total

Review 1.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors:  J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  Evaluation of a proposed technique to assess unscheduled DNA synthesis and genotoxicity.

Authors:  R A Goodlad; C Y Lee; M R Alison; C E Sarraf; M A Ghatei; S R Bloom; N A Wright
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

Review 4.  Acid suppression and claims of genotoxicity. What have we learned?

Authors:  R A Goodlad
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Effects of enprostil on gastric endocrine secretion during chronic administration of lansoprazole.

Authors:  N Omura; H Kashiwagi; T Aoki; K Omura; Y Fukuchi
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

Review 7.  Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach.

Authors:  Helge L Waldum; Øyvind Hauso; Øystein F Sørdal; Reidar Fossmark
Journal:  Dig Dis Sci       Date:  2014-12-06       Impact factor: 3.199

8.  Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.

Authors:  G Cadiot; T Lehy; P Ruszniewski; S Bonfils; M Mignon
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

Review 9.  Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis.

Authors:  J W Freston; K Borch; S J Brand; E Carlsson; W Creutzfeldt; R Håkanson; L Olbe; E Solcia; J H Walsh; M M Wolfe
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 10.  Pathophysiological effects of long-term acid suppression in man.

Authors:  R F McCloy; R Arnold; K D Bardhan; D Cattan; E Klinkenberg-Knol; P N Maton; R H Riddell; P Sipponen; A Walan
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.